BU and CY is a common conditioning regimen for allogeneic hematopoietic progenitor cell transplantation (HPCT). I.v. BU is increasingly used in place of the oral formulation for conditioning. We compared the outcomes of 135 consecutively treated AML and myelodysplastic syndrome patients who underwent allogeneic HPCT at our institution with BUCY2 using oral (n ¼ 93) or i.v. (n ¼ 42) BU, without dose adjustment. The i.v. BU patients had a lower incidence of any severity of oral mucositis (3 versus 55%, P ¼ 0.002) and severe mucositis (3 versus 24%, P ¼ 0.005). Other post transplant outcomes were comparable between the groups. In all 26 i.v. BU and 33 oral BU patients are alive; however, the median follow-up was significantly longer for the oral BU group. One-and two-year non-relapse mortality for the i.v. BU patients was 21% for both, and for the oral BU group was 23% and 29%, respectively. One-and two-year relapse mortality for the i.v. BU patients was 21% for both, and for the oral BU group was 24% and 29%, respectively. Substituting i.v. for oral BU reduces variability in drug exposure and potentially improves toxicity as suggested by our finding of significantly less oral mucositis and decreased severity with i.v. BU.
Introduction
BU is commonly used with CY as a conditioning regimen for allogeneic hematopoietic progenitor cell transplantation (HPCT). [1] [2] [3] More recently, i.v. BU has often replaced oral administration for transplant conditioning. [4] [5] [6] Advantages of the i.v. formulation of BU include avoidance of unpredictable or erratic intestinal absorption, with no first-past effect in the liver and a reduction in inter-and intrapatient bioavailability of the agent. [7] [8] [9] [10] Although targeted dosing of oral BU has previously been advocated, 11, 12 it has been demonstrated that predictable systemic exposure of parenteral BU may be achieved without pharmacokinetic monitoring. 4 I.v. BU has also been associated with a decreased incidence of sinusoidal obstruction syndrome and 100-day mortality after allogeneic HPCT. 5 We have previously reported that substitution of i.v. for oral BU was associated with a lower rate of relapse, and superior relapse-free and OS in relapsed or refractory non-Hodgkin's lymphoma patients undergoing autologous HPCT. 6 The objective of this study was to retrospectively compare post transplant outcomes between i.v. and oral BU when administered in combination with CY (BUCY2) for allogeneic HPCT conditioning in patients with AML and myelodysplastic syndrome (MDS).
Patients and methods
We retrospectively compared the outcomes of 135 consecutively treated adult AML and MDS patients who underwent allogeneic HPCT at our institution from May 2001 to October 2009. All patients were treated on allogeneic HPCT protocols that were reviewed and approved by the Cleveland Clinic's Institutional Review Board with signed informed consent obtained from all patients.
Patient eligibility criteria included a documented diagnosis of AML or MDS. In addition, patients were required to have an HLA-matched related donor or an 8/8 HLAmatched unrelated donor by DNA-based typing (HLA-A, -B, -Cw, -DR). Other eligibility requirements for HPCT included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 100 days based on the treating attending physician's assessment. Patients were required to have a normal serum creatinine, a serum total bilirubin o2 mg/dL and aspartate transaminase (AST) o2 times the upper limit of normal. They were also required to have a left ventricular ejection fraction of at least 45%, and a forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) X45% predicted. Patients were excluded from enrollment if they had central nervous system involvement with their disease, an HIV-positive status, pregnancy, or a concurrent medical or psychiatric illness that could not be controlled with appropriate therapy. Oral BU was administered at a dosage of 1 mg/kg every 6 h for 16 doses, while i.v. BU was administered at 0.8 mg/kg every 6 h for 16 doses (days À8 through À4) followed by CY 60 mg/kg/day Â 2 (days À3 and À2). The BU and CY doses were based on an adjusted body weight (((actual weightÀideal weight) Â 0.25) þ ideal weight). The actual weight was used for patients whose ideal body weight exceeded their actual weight. Mesna 60 mg/kg was administered on days À3 and À2. Patients received oral phenytoin for seizure prophylaxis. Filgrastim 480 mcg/day was started on day þ 5 and continued until ANC 4500/mL. GVHD prophylaxis consisted of CYA 100 mg twice daily, starting from day À1, and either mycophenolate mofetil 500 mg three times per day, starting from day þ 1, or MTX 5 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11 for patients with matched sibling donor transplants. Patients who had matched unrelated donor transplants received tacrolimus 0.03 mg/kg/day administered in a divided dose twice daily, starting from day À1 and MTX 5 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11.
Treatment

Definitions
Engraftment was defined as follows: neutrophil engraftment was achieved on the day of an ANC of 500/mL for two consecutive days; platelet engraftment was achieved on the day on which the platelet count was 20 000/mL independent of platelet transfusions for 3 consecutive days.
The modified Oral Mucositis Assessment Scale was used to evaluate patients for mucositis as previously described. 13, 14 The Oral Mucositis Assessment Scale assessed for erythema (none, mild, moderate, severe), and ulcers or pseudomembranes in the oral cavity. The scale ranges from 0 to 2 and those with a score of X0.5 are considered to have severe mucositis. Assessments for mucositis were performed three times a week from admission to the day of discharge. The maximum Oral Mucositis Assessment Scale score recorded during the transplant admission defined the severity of mucositis for a patient.
Relapse-free survival was defined as the time from transplantation until relapse, death or last follow-up. OS was defined as the interval from the date of transplantation until that of death or last follow-up. Non-relapse mortality included patients dying from causes other than relapsed disease.
Statistical analyses
Categorical variables are summarized by route of BU administration in the preparative regimen as frequency counts and percentages, and compared between groups using the w 2 test. Continuous variables are summarized as the mean, s.d., median and range, and compared between groups using the t-test or Wilcoxon rank sum test. The following outcomes were assessed: acute GVHD (grades 2-4 and 3-4), chronic GVHD (any, extensive), CMV infection, other infections, sinusoidal obstruction syndrome, pulmonary toxicity, mucositis (any and severe), relapse, relapse mortality, relapse-free survival, non-relapse mortality and OS.
OS and relapse-free survival were estimated using the Kaplan-Meier method and compared between the oral and i.v. BU groups via the log-rank test. All other outcomes were estimated using the cumulative incidence method and compared via the Pepe-Mori test.
Logistic regression analysis was used to identify univariable and multivariable risk factors for any mucositis and for severe mucositis. Stepwise analysis with a variable entry criterion of Po0.10 and a variable retention criterion of Po0.05 was used for the multivariable analysis. Cox proportional hazards analysis was used to assess the prognostic effect of BU route on each of the other outcomes. When this finding was significant, stepwise Cox analysis with a variable entry criterion of Po0.10 and a variable retention criterion of Po0.05 was used to identify multivariable prognostic factors.
Analyses were done using SAS software (SAS Institute, Inc., Cary, NC, USA). All statistical tests were two-sided, and Po0.05 was used to indicate statistical significance.
Results
Pre-transplant characteristics are shown in Table 1 . The i.v. BU patients were significantly older (P ¼ 0.037), and more commonly had unrelated donors (Po0.001) and a diagnosis of MDS (P ¼ 0.013) compared with those treated with oral BU. Transplant-related characteristics are shown in Table 2 . The i.v. BU group had a higher median CD34 þ cell dose infused (P ¼ 0.028) and more commonly received PBSC for their hematopoietic progenitor cell source (P ¼ 0.038) compared with those who received oral BU. In addition, the patients treated with i.v. BU more often received MTX instead of mycophenolate mofetil as part of their GVHD prophylaxis (Po0.001). There were no significant differences between the groups with regard to the length of transplant hospitalization and time until neutrophil and platelet engraftment.
A comparison of post transplant outcomes between the i.v. and oral BU groups is presented in Table 3 . The i.v. BU group experienced a significantly lower incidence of having any oral mucositis (Po0.001) and severe mucositis (P ¼ 0.015) than the oral BU group. This finding remained significant on multivariable analysis: oral/i.v. BU-any mucositis (odds ratio 27.29, 95% confidence interval (CI) 3.25-229.2, P ¼ 0.002) and severe mucositis (odds ratio 22.80, 95% CI 2.59-200.5, P ¼ 0.005). GVHD prophylaxis including MTX rather than mycophenolate mofetil was also a significant predictor for the development of mucositis on multivariable analysis: MTX/mycophenolate mofetilany mucositis (odds ratio 7.25, 95% CI 1.20-43.88, P ¼ 0.031) and severe mucositis (odds ratio 4.43, 95% CI 1.45-13.54, P ¼ 0.009).
Non-infectious pulmonary toxicity was observed in 4 (10%) patients in the i.v. BU group and in 3 (3%) patients in the oral BU group (P ¼ 0.052). The patients treated with i.v. BU included one patient whose open-lung biopsy revealed organizing pneumonia with early acute diffuse alveolar hemorrhage, but there was no evidence of infection or malignancy (7 months post transplant); one patient with extensive bilateral peribronchiolar ground glass opacities and no overt infection after bronchoscopic evaluation (2 months post transplant); one patient whose bronchoscopy was negative for infection and who was suspected to have bronchiolitis from the pulmonary evaluation (5 months post transplant); one patient's lung biopsy was negative for infection and findings revealed mild bronchiolar injury (5 months post transplant). The patients treated with oral BU who experienced pulmonary toxicity included one with pulmonary infiltrates without infection on bronchoscopic evaluation (B3.5 years post transplant); two with pulmonary infiltrates without identifiable infectious processes (23 and 17 months post transplant). None of these patients had received prior radiation therapy and none of them had pretransplant pulmonary infections.
Only two patients in each group (2% oral BU versus 5% i.v. BU, P ¼ 0.46) experienced sinusoidal obstruction syndrome. One of the i.v. BU patients had AML and 3 years previously had a reduced-intensity conditioning allogeneic HPCT for MDS with fludarabine and TBI; this patient also had prior therapeutic phlebotomy for transfusion-related iron overload and mild hepatic GVHD about 1.5 years previously that resolved and he was off Table 1 Pre-transplant characteristics immunosuppressant therapy. One other i.v. BU patient had MDS and the two oral BU patients had AML, but none of them had prior radiation therapy. None of the four patients had concomitant use of metronidazole, recent tyrosine kinase inhibitor therapy or other medications that are known or implicated as probably contributing to altering BU clearance. Although the oral BU group had a higher incidence of CMV infection (45 versus 24%, P ¼ 0.039), the route of BU administration was not found to be predictive of CMV infection on multivariable analysis. Independent predictors of CMV infection on multivariable analysis included donor relationship (unrelated/related donor: HR 0.39, 95% CI 0.18-0.87, P ¼ 0.022) and pre-transplant recipient/donor CMV status (positive/negative recipient or donor CMV status: HR 4.16, 95% CI 1.65-10.5, P ¼ 0.002). There were no significant differences between the i.v. and oral BU patients regarding other infections, acute or chronic GVHD, relapse, relapse-free survival or 100-day mortality.
Presently, 26 (62%) of the i.v. BU patients and 33 (35%) of the oral BU patients are alive. However, the median follow-up was substantially longer for the oral BU group (50 versus 13 months, Po0.001). Disease relapse was the most common cause of death for both the i.v. and oral BU patients, accounting for approximately 50% of deaths in each group (8 versus 29, respectively). The other causes of death for the patients treated with i.v. BU included two acute GVHD, two pulmonary toxicities, one sepsis, one cardiac arrest, one sinusoidal obstruction syndrome and one pneumonia. The remaining causes of death for those treated with oral BU were seven acute GVHD, six chronic GVHD, four sepsis, three pneumonia, three multiorgan failure, three pulmonary toxicities, one cardiac failure, one gastrointestinal hemorrhage, one fungal infection, one idiopathic encephalopathy and one suicide. Although the fraction of patients who died of GVHD was greater for the oral than the i.v. BU group (14% versus 5%, respectively), this difference was not significant when compared with the cumulative incidence estimates of GVHD-related deaths (P ¼ 0.11).
The median follow-up for patients who remain alive was significantly longer for the oral BU than for the i.v. BU group, 50 (range, 24-107) versus 13 (range, 5-27) months, respectively (Po0.001; see Figure 1 ). The 1-and 2-year non-relapse mortality for the i.v. BU patients was 21%, respectively, whereas that for the oral BU group was 23% and 29%, respectively. The 1-and 2-year relapse mortality for the i.v. BU patients was 21%, respectively, whereas that for the oral BU group was 24% and 29%, respectively. BU groups.
